| 期 |
栏目 |
标题 |
文件 |
| 编号 7 (2018) |
Articles |
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER |
|
| 卷 26, 编号 7 (2019) |
Articles |
PEComas: what are the treatment options? Literature review and personal experience |
|
| 卷 26, 编号 12 (2019) |
Articles |
The predictive value of nutritional deficiency in the treatment of patients with locally advanced stomach cancer |
|
| 卷 27, 编号 7 (2020) |
Articles |
Prospects for the use of immunotherapy in the treatment of head and neck squamous cell carcinoma |
|
| 卷 27, 编号 7 (2020) |
Articles |
Comparison of systems for evaluating the effectiveness of modern immunotherapy |
|
| 卷 27, 编号 11 (2020) |
Articles |
Ten-year experience of pharmacotherapy for soft tissue sarcomas |
|
| 卷 27, 编号 11 (2020) |
Articles |
The use of panitumumab in the treatment of chemoresistant metastatic sigmoid colon adenocarcinoma: a clinical case |
|
| 卷 28, 编号 7 (2021) |
Articles |
Experience of using prolgolimab in real clinical practice |
|
| 卷 28, 编号 7 (2021) |
Articles |
Assessment of the dynamics of immunological parameters at the beginning of therapy as prognostic and predictive factors in patients with melanoma |
|
| 卷 28, 编号 11 (2021) |
Articles |
Neoadjuvant immunotherapy for non-small cell lung cancer |
|
| 卷 29, 编号 7 (2022) |
Articles |
The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience |
|
| 卷 29, 编号 11/12 (2022) |
Articles |
Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma |
|
